On Aug. 18, 2021, RELIEF THERAPEUTICS reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, provided a safety update on ZYESAMIﾙ (aviptadil) which was being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.